Primary t(8;21)-negative AML cells showed an overall trend of being less sensitive to palbociclib compared with t(8;21)-positive AML ( Figures 7 A and S7 D), although there was some heterogeneity in response concomitant with reported sensitivity in other AML subtypes ( Placke et al., 2014 , Uras et al., 2016 , van der Linden et al., 2015 ).
← all excerpts
The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation.
1
—
—